301 related articles for article (PubMed ID: 25063910)
1. Antitumor platinum(IV) derivatives of oxaliplatin with axial valproato ligands.
Novohradsky V; Zerzankova L; Stepankova J; Vrana O; Raveendran R; Gibson D; Kasparkova J; Brabec V
J Inorg Biochem; 2014 Nov; 140():72-9. PubMed ID: 25063910
[TBL] [Abstract][Full Text] [Related]
2. New insights into the molecular and epigenetic effects of antitumor Pt(IV)-valproic acid conjugates in human ovarian cancer cells.
Novohradsky V; Zerzankova L; Stepankova J; Vrana O; Raveendran R; Gibson D; Kasparkova J; Brabec V
Biochem Pharmacol; 2015 Jun; 95(3):133-44. PubMed ID: 25888926
[TBL] [Abstract][Full Text] [Related]
3. Novel trans-platinum complexes of the histone deacetylase inhibitor valproic acid; synthesis, in vitro cytotoxicity and mutagenicity.
Griffith DM; Duff B; Suponitsky KY; Kavanagh K; Morgan MP; Egan D; Marmion CJ
J Inorg Biochem; 2011 Jun; 105(6):793-9. PubMed ID: 21497577
[TBL] [Abstract][Full Text] [Related]
4. Potentiation of mitochondrial dysfunction in tumor cells by conjugates of metabolic modulator dichloroacetate with a Pt(IV) derivative of oxaliplatin.
Zajac J; Kostrhunova H; Novohradsky V; Vrana O; Raveendran R; Gibson D; Kasparkova J; Brabec V
J Inorg Biochem; 2016 Mar; 156():89-97. PubMed ID: 26780576
[TBL] [Abstract][Full Text] [Related]
5. Platinum(IV) Complexes of
Papadia P; Micoli K; Barbanente A; Ditaranto N; Hoeschele JD; Natile G; Marzano C; Gandin V; Margiotta N
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32230896
[TBL] [Abstract][Full Text] [Related]
6. Modulatory effect of axial and equatorial ligands on antitumor activities of trans-1R,2R-diaminocyclohexane platinum(IV) complexes.
Siddik ZH; al-Baker S; Thai G; Khokhar AR
Anticancer Drug Des; 1994 Apr; 9(2):139-51. PubMed ID: 8166929
[TBL] [Abstract][Full Text] [Related]
7. Bis- and Tetrakis(carboxylato)platinum(IV) complexes with mixed axial ligands - synthesis, characterization, and cytotoxicity.
Hoffmeister BR; Hejl M; Adib-Razavi MS; Jakupec MA; Galanski M; Keppler BK
Chem Biodivers; 2015 Apr; 12(4):559-74. PubMed ID: 25879501
[TBL] [Abstract][Full Text] [Related]
8. Valuable insight into the anticancer activity of the platinum-histone deacetylase inhibitor conjugate, cis-[Pt(NH3)2malSAHA-2H)].
Brabec V; Griffith DM; Kisova A; Kostrhunova H; Zerzankova L; Marmion CJ; Kasparkova J
Mol Pharm; 2012 Jul; 9(7):1990-9. PubMed ID: 22591133
[TBL] [Abstract][Full Text] [Related]
9. Antiproliferative activity of Pt(IV)-bis(carboxylato) conjugates on malignant pleural mesothelioma cells.
Alessio M; Zanellato I; Bonarrigo I; Gabano E; Ravera M; Osella D
J Inorg Biochem; 2013 Dec; 129():52-7. PubMed ID: 24080480
[TBL] [Abstract][Full Text] [Related]
10. Multi-Acting Mitochondria-Targeted Platinum(IV) Prodrugs of Kiteplatin with α-Lipoic Acid in the Axial Positions.
Savino S; Marzano C; Gandin V; Hoeschele JD; Natile G; Margiotta N
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30011897
[TBL] [Abstract][Full Text] [Related]
11. Platinum(IV) prodrugs multiply targeting genomic DNA, histone deacetylases and PARP-1.
Xu Z; Hu W; Wang Z; Gou S
Eur J Med Chem; 2017 Dec; 141():211-220. PubMed ID: 29031068
[TBL] [Abstract][Full Text] [Related]
12. Dual-acting antitumor Pt(iv) prodrugs of kiteplatin with dichloroacetate axial ligands.
Savino S; Gandin V; Hoeschele JD; Marzano C; Natile G; Margiotta N
Dalton Trans; 2018 May; 47(21):7144-7158. PubMed ID: 29766157
[TBL] [Abstract][Full Text] [Related]
13. Platinum (II) complexes with stereochemically-defined thiepane dioxide diamine ligands as anticancer drugs.
Cerè V; Grossi L; Munari D; Pollicino S; Martelli L; Martelli M
Anticancer Res; 2006; 26(3A):1815-9. PubMed ID: 16827112
[TBL] [Abstract][Full Text] [Related]
14. An unsymmetric cisplatin-based Pt(iv) derivative containing 2-(2-propynyl)octanoate: a very efficient multi-action antitumor prodrug candidate.
Gabano E; Ravera M; Zanellato I; Tinello S; Gallina A; Rangone B; Gandin V; Marzano C; Bottone MG; Osella D
Dalton Trans; 2017 Oct; 46(41):14174-14185. PubMed ID: 28984330
[TBL] [Abstract][Full Text] [Related]
15. Influence of equatorial and axial carboxylato ligands on the kinetic inertness of platinum(IV) complexes in the presence of ascorbate and cysteine and within DLD-1 cancer cells.
Chen CK; Zhang JZ; Aitken JB; Hambley TW
J Med Chem; 2013 Nov; 56(21):8757-64. PubMed ID: 24107138
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, Structure, and Cytotoxicity of Oxaliplatin-Based Platinum(IV) Anticancer Prodrugs Bearing One Axial Fluoride.
Xu Z; Chan HM; Li C; Wang Z; Tse MK; Tong Z; Zhu G
Inorg Chem; 2018 Jul; 57(14):8227-8235. PubMed ID: 29943979
[TBL] [Abstract][Full Text] [Related]
17. Mechanistic and biological characteristics of different sugar conjugated 2-methyl malonatoplatinum(II) complexes as new tumor targeting agents.
Gao X; Liu S; Shi Y; Huang Z; Mi Y; Mi Q; Yang J; Gao Q
Eur J Med Chem; 2017 Jan; 125():372-384. PubMed ID: 27688191
[TBL] [Abstract][Full Text] [Related]
18. Quantitative measurement of the reduction of platinum(IV) complexes using X-ray absorption near-edge spectroscopy (XANES).
Hall MD; Daly HL; Zhang JZ; Zhang M; Alderden RA; Pursche D; Foran GJ; Hambley TW
Metallomics; 2012 Jun; 4(6):568-75. PubMed ID: 22569908
[TBL] [Abstract][Full Text] [Related]
19. A new orally active antitumor 1R,2R-cyclohexanediamine-platinum(IV) complex: trans-(n-valerato)chloro(1R,2R-cyclohexanediamine) (oxalato)platinum(IV).
Kizu R; Nakanishi T; Hayakawa K; Matsuzawa A; Eriguchi M; Takeda Y; Akiyama N; Tashiro T; Kidani Y
Cancer Chemother Pharmacol; 1999; 43(2):97-105. PubMed ID: 9923814
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic and antitumor effects of platinum(IV)-octanoato conjugates.
Novohradsky V; Zanellato I; Marzano C; Pracharova J; Kasparkova J; Gibson D; Gandin V; Osella D; Brabec V
Sci Rep; 2017 Jun; 7(1):3751. PubMed ID: 28623355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
